SAB Biotherapeutics (SABS) announced the appointment of David Zaccardelli, Pharm.D. to its Board of Directors as Chair of the Board and the appointment of Rita Jain, M.D., as an independent director, both effective immediately. Zaccardelli most recently served as President and CEO of Verona Pharma. Jain most recently served as Executive Vice President and Chief Medical Officer at ChemoCentryx.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics files $300M mixed securities shelf
- SAB Biotherapeutics Launches New $75 Million ATM Program
- SAB Biotherapeutics: Favorable SAB-142 Safety Profile and De-Risked Phase 2b Design Underpin Buy Rating
- SAB Biotherapeutics initiated with a Buy at Guggenheim
- SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial